Donald Trump has removed finasteride, a hair-loss treatment sold under the brand name Propecia, from his publicly disclosed medications. This change has been noted since he resumed office in January 2026, with the latest medical report released on June 4, 2026, not listing the drug. Trump's aides have not provided an explanation for its absence or confirmed whether he is still taking it. The White House stated that the report reflects all clinically relevant medications and that no significant health conditions were omitted. Robert Klitzman, a psychiatrist at Columbia University, expressed concerns regarding the lack of transparency about the president's health, particularly regarding the potential side effects of finasteride, which include depression and sexual dysfunction. Trump's health disclosures have faced scrutiny in the past, including his handling of COVID-19 and his medical evaluations. The latest report claims Trump is in 'excellent health' but has been criticized for lacking detailed supporting data.
Why this rating? · 12 signals
Signals flagged in the original
- loaded language: 'frantic speculation'
- loaded language: 'increasingly erratic'
- loaded language: 'mounting speculation'
- loaded language: 'raises transparency concerns'
- loaded language: 'raises significant questions'
- loaded language: 'less than forthcoming'
- framing: headline asserting a conclusion
- framing: selective emphasis on health concerns
Analyzed by our bias model Full breakdown ↓
Trump's Medical Report Excludes Hair-Loss Medication, Prompting Health Transparency Concerns
Donald Trump has excluded the hair-loss medication finasteride from his medical disclosures since taking office in January 2026. The White House claims the report includes all relevant medications, but experts have raised concerns about transparency regarding the president's health, particularly given the potential side effects of the medication.
No note attached
on this article.
Bias Analysis
Bias Indicators Removed
- ✕ loaded language: 'frantic speculation'
- ✕ loaded language: 'increasingly erratic'
- ✕ loaded language: 'mounting speculation'
- ✕ loaded language: 'raises transparency concerns'
- ✕ loaded language: 'raises significant questions'
- ✕ loaded language: 'less than forthcoming'
- ✕ framing: headline asserting a conclusion
- ✕ framing: selective emphasis on health concerns
- ✕ framing: loaded labels like 'frantic speculation'
- ✕ editorializing: nobody quite knows why
Original vs. Neutral
Trump Report No Longer Lists Hair-Loss Drug, Raising Health Transparency Questions
Trump's Medical Report Excludes Hair-Loss Medication, Prompting Health Transparency Concerns